# PDK2

## Overview
The PDK2 gene encodes the mitochondrial protein pyruvate dehydrogenase kinase 2, which is a member of the kinase family. This enzyme plays a crucial role in the regulation of the pyruvate dehydrogenase complex (PDC) by phosphorylating its E1 component, leading to the inactivation of the complex. This regulatory mechanism is vital for controlling the conversion of pyruvate to acetyl-CoA, thereby influencing the flow of carbon into the citric acid cycle and fatty acid synthesis (Knoechel2005Regulatory; Green2008Structural). PDK2 is characterized by a catalytic core with distinct N-terminal regulatory and C-terminal nucleotide-binding domains, and it functions as a homodimer (Tso2014Structureguided; Steussy2001Structure). The activity of PDK2 is modulated by various metabolites and interactions with the lipoyl domains of the PDC, playing a significant role in maintaining energy homeostasis in tissues with high metabolic demands (Klyuyeva2019Tissuespecific; Green2008Structural).

## Structure
Pyruvate dehydrogenase kinase 2 (PDK2) is a mitochondrial protein kinase involved in the regulation of the pyruvate dehydrogenase complex. The molecular structure of PDK2 is characterized by a catalytic core composed of two main domains: the N-terminal regulatory domain and the C-terminal nucleotide-binding domain. The N-terminal domain consists of a bundle of four amphipathic α-helices, while the C-terminal domain forms an α/β sandwich structure that includes the nucleotide-binding site (Klyuyeva2005The; Steussy2001Structure).

The C-terminal domain of PDK2 is similar to the nucleotide-binding domain of bacterial histidine kinases, although its catalytic mechanism resembles that of eukaryotic serine kinases and ATPases (Steussy2001Structure). PDK2 functions as a homodimer, with each monomer contributing to the formation of the active-site cleft between the two domains (Tso2014Structureguided).

The protein's structure is stabilized by hydrophobic interactions and hydrogen bonds, with specific motifs such as the G1, G2, and N-box playing crucial roles in nucleotide binding and catalysis (Steussy2001Structure). The carboxy-terminal tail of PDK2 is essential for its kinase activity, particularly in binding to the lipoyl-bearing domains of the pyruvate dehydrogenase complex (Klyuyeva2005The).

## Function
Pyruvate dehydrogenase kinase 2 (PDK2) is a key regulatory enzyme involved in the control of the pyruvate dehydrogenase complex (PDC) in mitochondria. PDK2 phosphorylates the E1 component of PDC, leading to its inactivation. This phosphorylation event is crucial for regulating the conversion of pyruvate to acetyl-CoA, thereby controlling the flow of carbon into the citric acid cycle and fatty acid synthesis (Knoechel2005Regulatory; Green2008Structural). 

PDK2 activity is modulated by various metabolites; it is activated by acetyl-CoA and NADH, while pyruvate, NAD+, and CoA serve as inhibitors (Green2008Structural). The enzyme's activity is also influenced by its interaction with the lipoyl domains of the E2 component of PDC, with reductive acetylation enhancing its function (Knoechel2005Regulatory). 

In healthy human cells, PDK2 plays a significant role in maintaining energy homeostasis, particularly in tissues with high metabolic demands such as muscle and brown adipose tissue (Klyuyeva2019Tissuespecific). Its regulation of PDC activity is essential for metabolic flexibility, allowing cells to adapt to varying energy requirements and conditions such as starvation and diabetes (Baker2000Marked; Green2008Structural).

## Clinical Significance
Alterations in the expression of the PDK2 gene have been implicated in several diseases and conditions. In the context of depression, PDK2 expression is upregulated, leading to increased phosphorylation of the pyruvate dehydrogenase (PDH) complex, which impairs glucose flux into the tricarboxylic acid (TCA) cycle. This metabolic dysfunction is observed in the frontal cortex of both chronic social defeat stress (CSDS) mice and major depressive disorder (MDD) patients, suggesting a role for PDK2 in the pathogenesis of depression (Wang2023Targeting).

In cancer, particularly head and neck cancer (HNC), PDK2 expression is significantly higher in advanced stages, contributing to the Warburg effect, a metabolic reprogramming that favors glycolysis over oxidative phosphorylation. This shift supports cancer cell growth and survival, and PDK2 is associated with increased cell proliferation, migration, and invasion abilities. PDK2's role in promoting stem-like properties and chemoresistance in cancer cells highlights its potential as a therapeutic target (Sun2022PDK1).

PDK2 is also involved in pulmonary arterial hypertension (PAH), where its expression is increased in the pulmonary arteries, contributing to metabolic remodeling characterized by suppressed glucose oxidation and increased glycolysis. This suggests that PDK2 could be a therapeutic target for PAH (Michelakis2017Inhibition).

## Interactions
PDK2, or pyruvate dehydrogenase kinase 2, is known to interact with several proteins, primarily within the pyruvate dehydrogenase complex (PDC). It phosphorylates the E1 component of PDC, thereby inhibiting its activity and regulating pyruvate oxidation (Green2008Structural). PDK2 binds tightly to the inner lipoyl-bearing domains (L2) of the dihydrolipoyl transacetylase component (E2) of PDC, which significantly enhances its kinase activity (Tuganova2007Recognition). This interaction is facilitated by specific amino acid residues in PDK2, which are crucial for binding to L2 and maintaining enhanced kinase activity in the PDC-bound state (Tuganova2007Recognition).

PDK2's interaction with the L2 domain is influenced by the presence of lipoyl groups, with reduced lipoyl groups leading to tighter binding and more binding sites (Hiromasa2003Facilitated). Potassium ions also play a significant role in enhancing the binding affinity of PDK2 for the L2 domain and nucleotides like ATP and ADP, facilitating cross-talk between nucleotide and L2-binding sites (Green2008Structural). These interactions are crucial for understanding the regulatory mechanisms of PDK2 and its role in metabolic processes.


## References


[1. (Knoechel2005Regulatory) Thorsten R. Knoechel, Alec D. Tucker, Colin M. Robinson, Chris Phillips, Wendy Taylor, Peter J. Bungay, Shane A. Kasten, Thomas E. Roche, and David G. Brown. Regulatory roles of the n-terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands,. Biochemistry, 45(2):402–415, December 2005. URL: http://dx.doi.org/10.1021/bi051402s, doi:10.1021/bi051402s. This article has 81 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi051402s)

[2. (Steussy2001Structure) C. Nicklaus Steussy, Kirill M. Popov, Melissa M. Bowker-Kinley, Robert B. Sloan, Robert A. Harris, and Jean A. Hamilton. Structure of pyruvate dehydrogenase kinase. Journal of Biological Chemistry, 276(40):37443–37450, October 2001. URL: http://dx.doi.org/10.1074/jbc.m104285200, doi:10.1074/jbc.m104285200. This article has 85 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m104285200)

[3. (Wang2023Targeting) Changshui Wang, Changmeng Cui, Pengfei Xu, Li Zhu, Hongjia Xue, Beibei Chen, and Pei Jiang. Targeting pdk2 rescues stress-induced impaired brain energy metabolism. Molecular Psychiatry, 28(10):4138–4150, May 2023. URL: http://dx.doi.org/10.1038/s41380-023-02098-9, doi:10.1038/s41380-023-02098-9. This article has 13 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41380-023-02098-9)

[4. (Hiromasa2003Facilitated) Yasuaki Hiromasa and Thomas E. Roche. Facilitated interaction between the pyruvate dehydrogenase kinase isoform 2 and the dihydrolipoyl acetyltransferase. Journal of Biological Chemistry, 278(36):33681–33693, September 2003. URL: http://dx.doi.org/10.1074/jbc.M212733200, doi:10.1074/jbc.m212733200. This article has 34 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M212733200)

[5. (Klyuyeva2019Tissuespecific) Alla Klyuyeva, Alina Tuganova, Natalia Kedishvili, and Kirill M. Popov. Tissue-specific kinase expression and activity regulate flux through the pyruvate dehydrogenase complex. Journal of Biological Chemistry, 294(3):838–851, January 2019. URL: http://dx.doi.org/10.1074/jbc.ra118.006433, doi:10.1074/jbc.ra118.006433. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.ra118.006433)

[6. (Tso2014Structureguided) Shih-Chia Tso, Xiangbing Qi, Wen-Jun Gui, Cheng-Yang Wu, Jacinta L. Chuang, Ingrid Wernstedt-Asterholm, Lorraine K. Morlock, Kyle R. Owens, Philipp E. Scherer, Noelle S. Williams, Uttam K. Tambar, R. Max Wynn, and David T. Chuang. Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the atp-binding pocket. Journal of Biological Chemistry, 289(7):4432–4443, February 2014. URL: http://dx.doi.org/10.1074/jbc.M113.533885, doi:10.1074/jbc.m113.533885. This article has 102 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M113.533885)

[7. (Baker2000Marked) Jason C. Baker, Xiaohua Yan, Tao Peng, Shane Kasten, and Thomas E. Roche. Marked differences between two isoforms of human pyruvate dehydrogenase kinase. Journal of Biological Chemistry, 275(21):15773–15781, May 2000. URL: http://dx.doi.org/10.1074/jbc.m909488199, doi:10.1074/jbc.m909488199. This article has 94 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m909488199)

[8. (Michelakis2017Inhibition) Evangelos D. Michelakis, Vikram Gurtu, Linda Webster, Gareth Barnes, Geoffrey Watson, Luke Howard, John Cupitt, Ian Paterson, Richard B. Thompson, Kelvin Chow, Declan P. O’Regan, Lan Zhao, John Wharton, David G. Kiely, Adam Kinnaird, Aristeidis E. Boukouris, Chris White, Jayan Nagendran, Darren H. Freed, Stephen J. Wort, J. Simon R. Gibbs, and Martin R. Wilkins. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Science Translational Medicine, October 2017. URL: http://dx.doi.org/10.1126/scitranslmed.aao4583, doi:10.1126/scitranslmed.aao4583. This article has 212 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/scitranslmed.aao4583)

[9. (Sun2022PDK1) Wan-Hsuan Sun, Yun-Hsuan Chen, Hou-Hsuan Lee, Yu-Wen Tang, and Kuang-Hui Sun. Pdk1- and pdk2-mediated metabolic reprogramming contributes to the tgfβ1-promoted stem-like properties in head and neck cancer. Cancer &amp; Metabolism, December 2022. URL: http://dx.doi.org/10.1186/s40170-022-00300-0, doi:10.1186/s40170-022-00300-0. This article has 7 citations.](https://doi.org/10.1186/s40170-022-00300-0)

[10. (Tuganova2007Recognition) Alina Tuganova, Alla Klyuyeva, and Kirill M. Popov. Recognition of the inner lipoyl-bearing domain of dihydrolipoyl transacetylase and of the blood glucose-lowering compound azd7545 by pyruvate dehydrogenase kinase 2. Biochemistry, 46(29):8592–8602, June 2007. URL: http://dx.doi.org/10.1021/bi700650k, doi:10.1021/bi700650k. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi700650k)

[11. (Klyuyeva2005The) Alla Klyuyeva, Alina Tuganova, and Kirill M. Popov. The carboxy-terminal tail of pyruvate dehydrogenase kinase 2 is required for the kinase activity. Biochemistry, 44(41):13573–13582, September 2005. URL: http://dx.doi.org/10.1021/bi0505868, doi:10.1021/bi0505868. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi0505868)

[12. (Green2008Structural) Todd Green, Alexei Grigorian, Alla Klyuyeva, Alina Tuganova, Ming Luo, and Kirill M. Popov. Structural and functional insights into the molecular mechanisms responsible for the regulation of pyruvate dehydrogenase kinase 2. Journal of Biological Chemistry, 283(23):15789–15798, June 2008. URL: http://dx.doi.org/10.1074/jbc.m800311200, doi:10.1074/jbc.m800311200. This article has 30 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m800311200)